University of Colorado Cancer Center


 

ASH 2023 Insights: "Results From a Ph1 Study of the All-Oral Regimen of CC-486 and Venetoclax For R/R AML"

157 views
December 14, 2023
Comments 0
Login to view comments. Click here to Login